Programme Thesis
Ocean State Labs is Rhode Island's first dedicated life sciences incubator, designed to catalyze early-stage biotech and medtech startups by providing lab space, equipment, mentorship, and access to a regional ecosystem anchored by Brown University, Rhode Island Hospital, and local investors. It exists to fill a gap in the Northeast's life sciences infrastructure outside of Boston/Cambridge, aiming to retain and grow innovative health ventures in Rhode Island.
Selection Criteria
- Eligibility: Early-stage life sciences or health-tech startup (pre-seed to Series A); must have a clear scientific or technological innovation with commercial potential.
- Scoring rubric (inferred from similar incubators): Scientific/technical merit (30%), market opportunity and competitive landscape (25%), team qualifications and diversity (20%), feasibility of milestones and use of incubator resources (15%), alignment with Rhode Island ecosystem and job creation potential (10%).
- Reviewer priorities: Likely favor ventures that can benefit from wet-lab or specialized equipment, have a strong IP position, and demonstrate a credible path to clinical or commercial milestones within 12-24 months.
Past Winners / Cohort Profiles
No specific past winners are listed on the provided page. As a new incubator (announced May 2026), Ocean State Labs likely has not yet announced its first cohort. Archetypes expected: therapeutics platforms (small molecule, biologics), diagnostics, medical devices, and digital health tools with a lab component. Named examples from similar Rhode Island programs (e.g., Brown's Nelson Center) include biotech startups like 'Cytovale' (sepsis diagnostics) and 'EpiVax' (immunoinformatics).
Ideal Candidate Fingerprint
A pre-seed or seed-stage life sciences startup with a validated proof-of-concept, a strong scientific founder (PhD/MD preferred), and a clear need for wet-lab space or specialized equipment. The venture should have a plausible path to a Series A within 18 months and a willingness to anchor in Rhode Island, leveraging local academic and hospital partnerships.
Recommended Framing
Eniola should position the venture as a computational biology platform that, while primarily dry-lab, requires access to wet-lab validation partners (e.g., for in vitro resistance testing) that Ocean State Labs can facilitate via its network of Rhode Island hospitals and research institutes. Emphasize the global health impact of predicting drug resistance (AMR, oncology) and how the incubator's resources (lab space, mentorship from pharma execs) can accelerate the SKEMPI 3K fine-tuning and Servier pilot. Highlight the founder's unique pharmacist+ML background as a differentiator in a space dominated by PhD-only teams.
Watch Out
The venture is not yet incorporated and is based in France, while Ocean State Labs is a US incubator likely requiring a US entity and physical presence in Rhode Island. The founder's priority is EU/France, so relocating or establishing a US subsidiary may be a barrier. Additionally, the venture is purely computational (no wet-lab need), which may not align with the incubator's life sciences focus on lab-based startups.